These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Comparative study of amlodipine vs. cilnidipine for the prevention of hepatic ischemia-reperfusion injury in rat model.
    Author: Fouda AM, Youssef AR, Sharaf Eldin O.
    Journal: Fundam Clin Pharmacol; 2018 Apr; 32(2):163-173. PubMed ID: 29172244.
    Abstract:
    Ca2+ signaling plays crucial role in ischemia and reperfusion (I/R) injury. Although blockade of L-type Ca2+ channels by amlodipine (AML) has been shown to suppress hepatic I/R injury in several animal models, information is still needed regarding the hepatoprotective effects of the dual L/N-type Ca2+ channel blockers, cilnidipine (CIL). We examined the effect of pretreatment with AML or CIL (100 μg/kg i.p.) 45 min before induction of 60 min of liver ischemia followed by reperfusion, on oxidative stress markers, liver enzymes, serum tumor necrosis factor-α, interleukin-1β, apoptosis markers, and nuclear factor KB after 6 and 24 h of hepatic reperfusion. Both drugs significantly ameliorated biochemical and histological markers of hepatic I/R injury, but protection with CIL was more significant at the 6-h time point where protection with AML outlasted that of CIL. Both drugs offered significant protection against hepatic I/R damage, but the protection with CIL seemed more potent but of shorter duration than that observed with AML possibly due to the shorter half-life of CIL.
    [Abstract] [Full Text] [Related] [New Search]